Taken form Motley Fool Article : Frost maybe setting OPK up to be SOLD soon...You decide
Frost maybe setting OPK up to be SOLD soon...You decide
Taken form Motley Fool Article
Probability of acquisition
Opko now has a lot of trial candidates in a variety of disease areas. One company that might acquire Opko might be Pfizer (NYSE: PFE). Pfizer needs new therapies for its pipeline. It is losing a lot of patents on drugs in the market, and it will need to acquire a company like Opko with a big pipeline of various drugs. Pfizer had lost the patent of Lipitor back in 2011, and at the peak point of its sales, the drug had achieved sales of $12 billion. Also, Pfizer has Viagra going off patent in the U.K., which will hurt sales. I think that Pfizer can benefit from acquiring the diversified pipeline of Opko to continue producing blockbuster drugs on the market.
Another big pharmaceutical company that would want to take a look at Opko is Merck (NYSE: MRK). Merck is struggling big time in the research and development of late stage drugs. Many analysts are saying that the company's osteoporosis drug odanacatib doesn't seem like it will lay out good results. Also, many analysts are skeptical of the cholesterol drug Vytorin. Vytorin is supposed to reduce risk of heart attack and strokes in patients. Merck, so far, has shelled out $8 billion and has had a huge blunder of misses in late stage trials. The company may benefit by acquiring Opko as it may give the struggling big pharma a huge boost.
Opko has a lot of mid stage and late stage products that will boost its value in the coming months. Long-term investors should do their due diligence and learn about the fundamentals of the company. Dr. Frost is known for building up small cap biotech stocks, and then selling them later to big pharma for billions of dollars. As mentioned, many big pharmaceuticals companies are seeking small cap biotechs to acquire so Opko would definitely be a good stock to own. Less
Sentiment: Strong Buy